[Comparison of the efficacy of different methods for the prevention of anti-D allo-immunization during pregnancy: targeted strategy limited to risk situations or associated with systematic prevention in the 3rd trimester]
- PMID: 16495834
[Comparison of the efficacy of different methods for the prevention of anti-D allo-immunization during pregnancy: targeted strategy limited to risk situations or associated with systematic prevention in the 3rd trimester]
Abstract
Background: In France, anti-Rh prophylaxis is currently based on systematic postnatal prevention which has validated efficacy (relative risk=0.04 versus placebo), associated with targeted antenatal prevention in the event of situations raising a risk of fetomaternal hemorrhage. In most industrialized countries, a systematic prevention policy is applied with immunoglobulin injections for the above cited situations and during the third trimester to cover the risk of spontaneous occult fetomaternal hemorrhage occurring at the end of pregnancy.
Objective: Compare the efficacy of two strategies for antenatal prevention.
Material and methods: Review of the literature of published comparative studies. Eleven studies were retained (two randomized trials, seven comparative studies, one before-after study, one population-based study) including more than 30,000 treated patients.
Results: Globally, immunization rate was to the order of 1.5% (1.2-1.9%) for targeted prevention limited to situations at risk and to the order of 0.2% (0-0.9%), all parities included, for systematic antenatal prevention. Comparative analyses have reported significant odds ratios of 0.20 and 0.37 in all subgroups.
Conclusion: Despite the heterogeneous nature of the published studies, available data are in favor of systematic prevention: either with a 300g dose at 28GW or 100g at 28GW and 34GW complementary to the postnatal prevention. Few data are available on the real perinatal benefit of systematic prevention.
Similar articles
-
[Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].J Gynecol Obstet Biol Reprod (Paris). 2006 Feb;35(1 Suppl):1S123-1S130. J Gynecol Obstet Biol Reprod (Paris). 2006. PMID: 16495838 Review. French.
-
[Epidemiology of anti-D allo-immunization during pregnancy].J Gynecol Obstet Biol Reprod (Paris). 2006 Feb;35(1 Suppl):1S87-1S92. J Gynecol Obstet Biol Reprod (Paris). 2006. PMID: 16495833 Review. French.
-
[Economic analysis of the prevention of anti-D immunization].J Gynecol Obstet Biol Reprod (Paris). 2006 Feb;35(1 Suppl):1S104-1S111. J Gynecol Obstet Biol Reprod (Paris). 2006. PMID: 16495835 Review. French.
-
[Adverse effects and patient information].J Gynecol Obstet Biol Reprod (Paris). 2006 Feb;35(1 Suppl):1S112-1S118. J Gynecol Obstet Biol Reprod (Paris). 2006. PMID: 16495836 Review. French.
-
[Current viewpoints in the anti-D prevention of rhesus alloimmunization in the pregnant woman and of hemolytic disease of the newborn infant (a review of the literature)].Akush Ginekol (Sofiia). 1986;25(3):84-90. Akush Ginekol (Sofiia). 1986. PMID: 3019168 Review. Bulgarian. No abstract available.
Cited by
-
Usefulness of Non-Invasive Fetal RHD Genotyping towards Immunoprophylaxis Optimization.Transfus Med Hemother. 2018 Nov;45(6):423-428. doi: 10.1159/000490156. Epub 2018 Oct 30. Transfus Med Hemother. 2018. PMID: 30800032 Free PMC article.
-
The importance of antenatal prevention of RhD immunisation in the first pregnancy.Blood Transfus. 2014 Jul;12(3):410-5. doi: 10.2450/2014.0167-13. Epub 2014 Jan 2. Blood Transfus. 2014. PMID: 24887219 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical